Logo

GE Healthcare Creates Molecular Dx Unit, Moves Discovery Systems Research to NY

Aug 17, 2004

NEW YORK, Aug. 17 (GenomeWeb News) – GE Healthcare said today it has established a Molecular Diagnostics business unit, based in Piscataway, NJ, and has appointed Trevor Hawkins as president of Molecular Diagnostics.

Separately, the Little Chalfont, UK, unit of General Electric said that it has moved research activities of its Discovery Systems business to the GE Global Research Center, in Niskayuna, New York.

These moves come several months after GE’s acquisition of Amersham Bioscience in April, and its reorganization of GE Healthcare.

“Both of these moves underscore the strategic importance of functional biology and molecular diagnostics,” Peter Loescher, President and CEO of GE Healthcare said in a statement. “By transferring Discovery Systems’ Research activities to GE Global Research, we benefit from unparalleled scientific and technological resources. Through the establishment of our Molecular Diagnostics business unit, we will accelerate the accuracy and speed of determining disease predisposition and diagnosis.”

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.